The circumstances in 2005 forced an amendment to section 3(d) in the Indian Patent Law, 1970. Discuss how it has been utilized by the Supreme Court in its judgment rejecting Novarti's patent application for “Glivec“. Discuss briefly the pros and cons of the decision.
Introduction
Section 3(d) of the Indian Patent Law, 1970, prevents "evergreening" by disallowing patents for new forms of known substances unless they demonstrate significantly enhanced therapeutic efficacy.
Body
Circumstances and 2005 Amendment
The 2005 amendment clarified this provision, ensuring trivial modifications could not extend patent life, promoting access to affordable medicines.
Supreme Court's Glivec Judgment
The Supreme Court applied Section 3(d) to reject Novartis's patent for Glivec (Imatinib Mesylate). It ruled Glivec, a beta-crystalline form of a known drug, did not show significantly enhanced therapeutic efficacy, failing the 3(d) test.
Pros of the Decision
- Ensured affordability and accessibility of life-saving drugs.
- Boosted the domestic generic drug industry.
- Upheld public health interests over corporate profits.
Cons of the Decision
- Raised concerns among multinational pharmaceutical companies regarding India's IPR regime.
- Potentially discouraged R&D investment in India.
- Perceived by some as a barrier to innovation.
Conclusion
The judgment balanced innovation incentives with public health, reinforcing India's commitment to affordable healthcare.
154 words · target ~150
The directive 'Discuss' requires candidates to present a detailed account of the topic, examining various aspects, arguments, and implications, often requiring a balanced perspective.
Suggested structure
Introduction to Section 3(d) of Indian Patent Law, 1970
Circumstances leading to the 2005 amendment/clarification of Section 3(d)
Supreme Court's application of Section 3(d) in the Novartis Glivec judgment
Pros of the Supreme Court's decision
Cons of the Supreme Court's decision
Conclusion/Broader implications
Key points
Section 3(d) prevents 'evergreening' of patents by disallowing patents for new forms of known substances unless they show significantly enhanced therapeutic efficacy.
The 2005 amendment clarified that new forms of known substances must demonstrate enhanced efficacy to be patentable, addressing concerns about trivial modifications extending patent life.
Novartis sought a patent for Glivec (Imatinib Mesylate), a beta-crystalline form of a known drug, claiming it was a new invention.
Supreme Court rejected the patent, ruling that Glivec did not demonstrate significantly enhanced therapeutic efficacy over the known substance, thus failing the 3(d) test.
Pros: Ensured affordability and accessibility of life-saving drugs, boosted the generic drug industry, upheld public health interests over corporate profits.
Cons: Raised concerns among multinational pharmaceutical companies about India's IPR regime, potentially discouraging R&D investment in India, perceived as a barrier to innovation by some.
Common mistakes
Lack of specific knowledge about Section 3(d) and its 2005 amendment.
Incorrectly stating the details of the Novartis Glivec case or the Supreme Court's reasoning.
Failing to provide a balanced discussion of both pros and cons of the decision.
Not linking the amendment directly to the court's judgment and its implications.
Difficulty: Hard — The question requires specific knowledge of a particular section of Indian Patent Law (Section 3(d)), its amendment, and a landmark Supreme Court judgment (Novartis Glivec case). It also demands a balanced discussion of the socio-economic implications (pros and cons), which requires analytical depth beyond mere factual recall.